ISSN: 2332-0877

Journal of Infectious Diseases & Therapy
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Research Article   
  • J Infect Dis Ther

Characteristics of the COVID-19 Patients Treated at Gulu Regional Referral Hospital, Northern Uganda: A Cross-Sectional Study

Christopher Okot1,2, Steven Baguma1,2, Nelson Alema Onira3, Willis Odong Agings1, Baifa Arwinyo1,2, James Elima2, Paska Apiyo1,2, Paska Layet1,4, Francis Pebalo Pebolo1,5, Denis Acullu1,6, Johnson Nyeko Oloya1, Freddy Wathum Drinkwater Oyat1, Janet Oola1,7, Judith Aloyo1,8, Eric Nzirakaindi Ikoona9 and David Lagoro Kitara1,10*
1Uganda Medical Association (UMA), UMA Acholi Branch, Gulu City, Uganda
2Department of Obstetrics and Gynecology, Gulu Regional Referral Hospital, Gulu City, Uganda
3Department of Anatomy, Gulu University, Gulu City, Uganda
4Department of Medicine, St. Mary’s Hospital, Lacor, Gulu City, Uganda
5Department of Reproductive Health, Gulu University, Gulu City, Uganda
6Department of Radiation Oncologist, Aga Khan Hospital, Mombasa, Kenya
7Department of Global Health, Dowman Drive Atlanta, Georgia, United States
8Rhites-N, Acholi, Gulu City, Uganda
9ICAP, Columbia University, Freetown, Sierra Leone
10Department of Surgery, Gulu University, Gulu City, Uganda
*Corresponding Author: David Lagoro Kitara, Department of Surgery, Gulu University,Faculty of Medicine, Gulu City, Uganda, Email: klagoro2@gmail.com

Received: 20-Dec-2021 / Accepted Date: 03-Jan-2022 / Published Date: 10-Jan-2022

Abstract

Background: Coronavirus Disease 2019 (COVID-19) is a severe respiratory disease that results from infection with a new coronavirus (SARS-CoV-2). One of the most critical issues related to the COVID-19 is the high rate of spread, millions of people have been infected around the world, and hundreds of thousands of people have died till now. However, reports from Africa paint a different picture of the SARS-CoV-2 and its effects on the population.

Objectives: The objective of this study was to describe the characteristics of the COVID-19 patients treated at the Gulu Regional Referral Hospital and determine factors associated with COVID-19 manifestations, socio-demographic characteristics, and treatment outcomes from March 2020 to October 2021.

Methods: A retrospective data abstraction of all COVID-19 hospital admissions registered in the Gulu Health Management Information System (HMIS) database and other tools were conducted. The period of study was from March 2020 to October 2021. Data that met the inclusion criteria were consecutively abstracted from the Gulu Hospital HMIS database. A local IRB approved the study. SPSS version 25.0 was used for data analysis, and a p-value of 0.05 was considered significant.

Results: Data suggests there were three waves of COVID-19 in Uganda. Those with comorbidities, e.g., Diabetes mellitus 38(5.7%), hypertension 83(12.5%), cardiovascular diseases 58(8.7%), HIV and AIDS 61(9.2%), and other comorbidities such as liver cirrhosis and Hepatitis B 40(6.0%) were more susceptible and presented with more severe forms of the disease. Antibiotics 662(99.7%), steroids 73(11.0%), vitamin C 564(84.9%), Ivermectin 7(1.1%), and Vitamin D 24(3.6%) were the most used medicines for the treatment of COVID-19 patients. Most COVID-19 patients were unvaccinated 661(99.5%). However, the recovery rate was 632(95.2%). The commonest complications were pneumonia 60(9.0%), chronic fatigue 49(7.4%), acute respiratory distress syndrome (ARDS) 37(5.6%), depression 20(3.0%), systemic infections 19(2.9%), nightmares 15(2.3%) and septic shock 8(1.2%). The Adjusted Odds Ratios (AOR) on factors associated with recovery were treatment with steroids AOR=138.835 at 95% CI:12.258-1572.50;p<0.000 and Vitamin D AOR=0.016 at 95% CI:1.902- 520.98; p=0.016.

Conclusion: This study showed successful management of COVID-19 patients in low-resource settings with a recovery rate of 95.2%. The admission pattern suggests Uganda had three waves of COVID-19, contrary to the official government position of two. Treatment with steroids and Vitamin D is associated with the recovery among COVID-19 patients. There is a need to conduct more extensive studies on the role played by the two drugs in the successful recovery of COVID-19 patients.

Keywords: COVID-19; Comorbidities; Treatment; Complications; Steroids; Vitamin-D

Introduction

Coronavirus Disease 2019 (COVID-19) is a severe respiratory disease that results from infection with a new coronavirus (SARSCOV- 2) [1]. One of the most critical issues related to the COVID-19 is the high rate of spread, millions of people have been infected around the world, and hundreds of thousands of deaths till now have been recorded [1]. Patients suffering from different symptoms like fever, dry cough, and fatigue are usually mild in about 80% of cases. Still, the more severe cases may develop respiratory distress or respiratory failure, hence the increased need for intensive care unit (ICU) services [1].

The severity of the disease is related to the age and comorbidities of the infected person; elderly persons are affected more severely with a need for ICU services [2]. The severity of symptoms is also related to its duration, where for mild cases, symptoms may last for two weeks, while for severe cases, it ranges from 3 to 6 weeks [3]. Direct contacts to confirmed cases are the disease’s primary way of spreading because the SARS-COV-2 is transmitted through exhaled air and aerosols [4]. Diagnosis of COVID-19 is conducted using Reverse Transcriptase Polymer Chain Reaction (RT-PCR), Computed Tomography (CT) scan, and blood tests [5]. Supportive treatment is the primary choice for mild cases, including antibiotics, vitamins, trace elements, and antipyretics [6]. At the same time, oxygen therapy with or without mechanical ventilation is introduced and individualized according to each case [6].

Many drugs have been included in clinical trials to act as antiviral agents to the coronavirus disease. Still, no precise results indicate the confirmed effect for any investigated drugs [7-9]. In addition to symptomatic therapy, corticosteroids as an anti-inflammatory agent have been found to play a vital role in the management of severe cases of the COVID-19 [10].

Thousands of infected patients have recovered from the disease. This recovery is confirmed by conducting another RT-PCR test or by the absence of the symptoms of the disease for several days. However, few documented studies in Uganda provide information on the clinical characterization of COVID-19 cases, treatment outcomes, and factors associated with clinical presentations and treatment outcomes.

The objective of this study was to describe the characteristics of the COVID-19 patients treated at the Gulu Regional Referral Hospital and determine factors associated with the COVID-19 manifestations, socio-demographic characteristics, and treatment outcomes.

Materials and Methods

Study site

This study was conducted in Gulu Regional Referral Hospital in Northern Uganda, covering admissions of COVID-19 patients from March 2020 to October 2021. Gulu Hospital is a regional referral centre for patients from Northern Uganda. However, it receives patients from neighbouring countries, for example, South Sudan and the Democratic Republic of Congo (DR Congo). It is also a teaching hospital for Gulu University Medical School and many other health training institutions in the region. It is a 394-bed capacity hospital with outpatient and inpatients services estimated at 120,000 patients every year. The Hospital has specialized units such as internal medicine, surgery, paediatrics, reproductive health, TB, HIV, cardiac, chest, dental, dermatology, sickle cell disease, diabetes, hypertension, ear, nose and throat, nutrition, accident and emergency, laboratory, ophthalmology, mental health, and orthopaedic clinics that consultants from Gulu Regional Referral Hospital and Gulu University manage.

Gulu Regional Referral Hospital was designated by the Ugandan Ministry of Health as a treatment centre for COVID-19 patients in March 2020 when COVID-19 was declared a pandemic. As a result, a particular treatment unit for the management of COVID-19 (Gulu CTU) was established with a fully-fledged high dependency unit (HDU), with oxygen supply and staff to manage the department. The team leader for the Gulu CTU is a consultant physician who cares for all the COVID-19 patients admitted to the unit. In addition, the Ugandan Ministry of Health and WHO health experts provided additional support for managing the COVID-19 patients at the centre using standard protocols developed and practiced in Uganda.

Study design

A retrospective data review and abstraction of all COVID-19 hospital admissions registered in the Gulu Health Management Information System (HMIS) database and other tools were conducted. The period of the review was March 2020 to October 2021. Established by the Ugandan Ministry of Health, HMIS has been the primary source of information on COVID-19 hospital admissions and deaths. COVID-19 notification is compulsory in Uganda, and the emergency operation centre at the Uganda National Public Health Institute receives reports on patients admitted to both public and private hospitals with COVID-19.

Sources of data

For the period of this study, COVID-19 patients admitted to Gulu Regional Referral Hospital with COVID-19 were estimated at nine hundred and forty-four (944). We included every patient registered in the HMIS database. Information on individual's socio-demographic characteristics, self-reported symptoms, signs, comorbidities, COVID-19 Treatment Unit (CTU) admissions, ICU admissions, and ventilatory support, dates of symptoms’ onset, dates of hospital admissions, dates of discharges/ releases, duration of the hospital stay, the reported circumstances of contracting the coronavirus, the vaccination status and hospital outcomes (deaths, referrals, and releases/discharges) were documented. HMIS data were accessed, which were already de-identified and publicly available documents. Following ethically agreed principles on open data access, this review did not require stringent ethical approval in Uganda as we mainly worked on records with no identifiers included. However, we obtained ethical and administrative licenses from the Gulu Regional Referral Hospital Institution and Ethics Review Committee to access the archived Gulu Hospital data on COVID-19 patients.

Selection criteria

Inclusion criteria:

• Confirmed cases of COVID-19 with RT-PCR.

• Records of patients 12 years and above.

• Completed information on the chart and other medical tools.

• Admission records.

Exclusion criteria:

We excluded:

• Incomplete records.

• Participants below 12 years.

Selection of records: The medical records for the COVID-19 patients in Gulu Regional Referral Hospital archives were accessed. The selection of the COVID-19 patients' files was conducted consecutively and reviewed by the research team. The selection criteria were applied to each admission file (a total of nine hundred and forty-four files); seven (7) were excluded due to lack of RT-PCR results; thirteen (13) patients were less than twelve years; fifty-six (56) patients had incomplete files; ninety-six (96) patients appeared in HMIS database without admission files; one hundred and five (108) patients had insufficient medical history on the file, and finally a total of six hundred and sixty-four (664) files were included in the participating medical records for this research.

Sample size: We determined the sample size for the study population using the selection criteria on the medical records. Six hundred and sixtyfour (664) records were included as the sampled population.

Training of research assistants: To obtain excellent and clean information from these COVID-19 patients' medical files, the research team trained the research assistants who were four in number (two medical officers, one clinical officer, and one nurse) on how to use the selection criteria, accurately record data from the admission forms and exclude forms that were considered incomplete. The research assistants were trained on infection, prevention, and control of COVID-19 and were required to use facemasks, eye shields, and sanitizers during and after reviewing documents. The corresponding author supervised the data collection exercise from the beginning to the end, ensuring that he checked every file to confirm the completeness of the data collected.

Procedures for data collection: Consecutively registered COVID-19 patients treated at Gulu Regional Referral Hospital with a positive quantitative RT-PCR test result for SARS-CoV-2 admitted to Gulu Hospital were recruited. SARS-CoV-2 diagnostic tests followed National and International standards. They were conducted in certified laboratories of Gulu Regional Referral Hospital and Uganda Virus Research Institute (UVRI) as the Ugandan Ministry of Health protocols required.

Variables for the study: The dependent variables for this study were treatment outcomes (alive or dead). The independent variables were the socio-demographic characteristics of the COVID-19 patients (age, sex, occupation, religion, tribe, districts, and level of education), comorbidities and treatments used, oxygen saturation at admission, date of discharge from the hospital, duration of hospital stay, disease severity, and others), clinical presentations (signs and symptoms), vaccination status, residences, and circumstances under which COVID-19 patients contracted the coronavirus.

Data analysis: The analysis period was from the epidemiological week (starting month and date of March 2020) to the epidemiological week (until month and date of October 2021). The analysis was pre-specified and defined before reading the medical data in the Gulu Regional Referral Hospital records. The sample size was all patients (aged ≥ 12 years) with confirmed COVID-19 diagnosis who were admitted to the Gulu Hospital and registered in the database between the epidemiological weeks of March 2020 and October 2021.

Means, standard deviations, bar graphs, histograms, frequencies, and percentages were used to summarize continuous variables, while frequencies and proportions were calculated for categorical variables. Ageadjusted and sex-adjusted rates for each district by the direct method using the estimated Ugandan population for 2020 as a reference were calculated.

We used the Chi-Square tests at bivariate analysis to observe associations between independent and dependent variables at 95% confidence Intervals. Factors with p-values less or equal to 0.2 were entered into a multivariable regression analysis to determine factors associated with COVID-19 patients treated at GRRH. However, the Gulu Hospital HMIS data contained much-missing information for some variables, such as reported symptoms, medicines used, and comorbidities. Therefore, we used additional GRRH records to fill in the missing data. Also, in the post hoc analysis, we evaluated the missing data pattern and conducted a sensitivity analysis via multiple imputations by chained equations, generating 30 imputed datasets. SPSS version 25.0 was used for data analysis, and various imputations were performed utilizing the STROBE guideline recommendations. In addition, Adjusted Odds Ratios (AOR) for independent variables were calculated for the COVID-19 patients treated at the Gulu Regional Referral Hospital from March 2020 to October 2021.

Ethical considerations: This retrospective data review of COVID-19 patients' medical files at the Gulu Regional Referral Hospital was approved by the Gulu Regional Hospital Institutional, Ethics, and Review Committee.

Results

This study abstracted six hundred and sixty-four (664) medical records of COVID-19 patients treated at the Gulu Regional Referral Hospital from March 2020 to October 2021. Only medical records of COVID-19 patients that met the inclusion criteria for the study were included. Most COVID-19 patients treated at the GRRH recovered from the disease with a recovery rate of 632(95.2%) and a mortality rate of 32(4.8%). In addition, most COVID-19 patients treated at the Hospital were unvaccinated 661(99.5%) for COVID-19.

In Figure 1, there were three waves of COVID-19 in Gulu, Northern Uganda, and these were May and September in 2020. In addition, there was a small observable wave in July 2021.

In Figure 2, COVID-19 discharges from the CTU of Gulu Regional Referral Hospital mirrored the admission pattern where June, October of 2020, and July 2021 registered the most releases from the CTU.

Figure 3 shows the peak duration of Hospital stays (days) among COVID-19 patients treated at GRRH as 16 days.

In Table 1, most COVID-19 patients treated at the Gulu Regional Referral Hospital from March 2020 to October 2021 were males 443(66.7%), age group 30-39 years old 204(30.7%); Certificate holders of education 152(32.6%), Acholi 386(59.2%), Catholics 95(46.3%), Civil Servants 97(19.0%) and from Gulu District 226(34.0%).

Variables Frequency Percent (%)
Gender
Male 443 66.7
Female 221 33.3
Age (years) 664 100
<20 41 6.2
20-29 139 20.9
30-39 204 30.7
40-49 151 22.7
>50 129 19.4
Subtotal 664 100
Tribes
Acholi 386 59.2
Lango 19 2.9
Baganda 70 10.7
Madi 22 3.4
Others 155 23.8
Subtotal 652 100
Religion
Catholics 95 46.3
Protestants 51 24.9
Born Again 6 2.9
Muslims 44 21.5
Others 9 4.4
Subtotal 205 100
The highest level of education attained
No formal education 64 13.7
Primary 43 9.2
Secondary 59 12.7
Certificates 152 32.6
Diploma 65 13.9
Degrees 72 15.5
Postgraduate degrees 11 2.4
Subtotal 466 100
Occupation
Business 95 18.6
Civil Servants 97 19
Health workers 47 9.2
Teachers 7 1.4
Uniformed security forces 27 5.3
Peasant Farmers 76 14.9
Others 161 31.6
Subtotal 510 100
Districts
Agago 9 1.4
Amuru 59 8.9
Gulu 226 34
Kitgum 50 7.5
Lamwo 16 2.4
Nwoya 16 2.4
Omoro 37 5.6
Pader 24 3.6
Others 227 34.2
Subtotal 664 100

Table 1: Socio-demographic characteristics of COVID-19 patients treated at Gulu Regional Hospital.

Tables 2 and 3 shows drugs used for the treatment of COVID-19 at GRRH: antibiotics 662(99.7%), Vitamin C 564(84.9%), steroids 73(11.0%), Vitamin D 24(3.6%), Ivermectin 7(1.1%), and Aspirin 2(0.3%) in the descending order.

Symptoms and signs Yes (%) No (%)
Cough 331(49.8) 331(49.8)
Tiredness 128(19.3) 536(80.7)
Body aches and pains 192(28.9) 472(71.1)
Sore throat 117(17.6) 546(82.2)
Headache 225(33.9 438(66.1)
Loss of taste 44(6.6) 619(93.2)
Loss of smell 43(6.5) 621(93.5)
Shortness of breath 171(25.8) 493(74.2)
Loss of speech 20(3.0) 644(97.0)
Vomiting 21(3.2) 643(96.8)
Diarrhoea 20(3.0) 643(96.8)
Conjunctivitis 1(0.2) 662(99.7)
Comorbidities
Diabetes Mellitus (DM) 38(5.7) 626(94.3)
Chronic Obstructive Pulmonary Diseases (COPDs) 38(5.5) 656(94.5)
Hypertension 83(12.5) 581(87.5)
Other Cardiovascular Diseases (CVDs), e.g., Stroke and heart failures                                                58(8.7) 605(91.3)
Obesity 3(0.5) 661(99.5)
Asthma 15(2.3) 648(97.7)
Cancers 4(0.6) 648(99.4)
HIV and AIDS 61(9.2) 603(90.8)
Other comorbidities (Hepatitis B, Liver diseases, Severe malaria) 40(6.0) 624(94.0)
Systolic blood pressure (mmHg)    
<120 177(26.7)
121-140 298(44.9)
>140 169(25.5)
Diastolic blood pressure (mmHg)
< 80 329(49.5)
81-120 183(27.6) 
121-140 132(19.9)
Duration of symptoms (days)
1-7 days 236(63.1)
8-14 days 107(28.6)
15-21 days 22(5.9)
22-28 days 16(2.4)
>28 days 9(2.4)
Duration of hospital stay (Weeks)
0-1 318(47.9)
2-4 300(45.2)
>4 24(3.6)
Oxygen saturation (SpO2) of COVID-19 patients at admission
<80 9(1.4)
80-95 85(12.8)
>96 403(60.7)
Clinical presentations
Symptomatic 509(76.7)
Asymptomatic 154(23.2)
Body Temperature (0°C)
< 37.2 525(79.1)
37.3-38.9 11(1.7)
>39 2(0.3)
Random blood sugar level (RBS)
Normal (<8 mmol/L) 11(25.6)
Abnormal (>8mmol/L) 32(74.4)
Fasting Blood Sugar level (FBS)
Normal (<7 mmol/L) 9(36.0)
Abnormal (>7mmol/L) 16(64.0)
The circumstance of contracting the virus (at Elegu border point with international truck drivers) 50(7.5)
Number of COVID-19 patients who died from Gulu Regional Referral Hospital 32(4.8)
Number of unvaccinated COVID-19 patients treated at Gulu Hospital 661(99.5)

Table 2: Symptoms and comorbidities among COVID-19 patients treated at Gulu Regional Hospital.

Medicine used Frequency (n=664) Percent (%)
Hydroxychloroquine 0 0
Chloroquine 0 0
Steroids 73 11
Aspirin 2 0.3
Antibiotics 662 99.7
Vitamin D 24 3.6
Vitamin C 564 84.9
Ivermectin 7 1.1

Table 3: Drugs used for the treatment of COVID-19 patients at Gulu Regional Referral Hospital.

In Table 4, complications observed in COVID-19 patients treated at GRRH were pneumonia 60(9.0%), chronic fatigue 49(7.4%), acute respiratory distress syndrome (ARDS) 37(5.6%), acute respiratory failure 30(4.5%); depression 20(3.0%), systemic infections 19(2.9%), nightmares 15(2.3%) and septic shock 8(1.2%).

 Complications Frequency (n=664) Percent (%)
Depression 20 3
Nightmares 15 2.3
Multiple Organ Failure (MOF) 5 0.8
Acute Respiratory Failure (ARF) 30 4.5
Pneumonia 60 9
Acute Respiratory Distress Syndrome (ARDS) 37 5.6
Acute Liver Injury 2 0.3
Acute Cardiac Injury 2 0.3
Systemic infections 19 2.9
Acute kidney injury 5 0.8
Blood clots 3 0.5
Chronic fatigue 49 7.4
Septic Shock 8 1.2
Disseminated Intravascular Coagulation (DIC) 3 0.5

Table 4: Complications in the COVID-19 patients treated at the Gulu Regional Hospital.

In Tables 5 and 6, most COVID-19 patients treated in GRRH were in the hospital for one week 216(44.9%); oxygen saturation (SpO2) at admission was >96 394(81.9%); did not use Aspirin 479(99.6%), steroids 415 (86.3%), Garlic 480 (99.8%), Lemon 478(99.4%), Ivermectin 474(98.4%), Vitamin D 458(95.2%), and steaming 479 (99.6%) but used Antibiotics 480(99.8%) for treatment.

Variables Chi-square df p-value
Cross tabulations between duration of symptoms (days) and other variables
Symptomatic patients 10.301 4 0.036
Age of patients 14.585 16 0.555
Gender of patients 6.284 4 0.179
The highest level of education attained 30.42 32 0.547
Cross tabulations between Diabetes mellitus and other variables
Symptomatic patients 5.314 1 0.021
Age of patients 22.66 4 0
Gender of patients 0.016 1 0.901
The highest level of education attained 32.532 8 0
Cross tabulations between Chronic obstructive pulmonary diseases (COPDs) and other variables
Symptomatic patients 0.014 1 0.905
Age of patients 6.195 4 0.185
Gender of patients 6.346 1 0.032
The highest level of education attained      
Cross tabulations between other cardiovascular diseases (CVDs) and other variables
Symptomatic patients 4.462 1 0.035
Age of the patients 22.562 1 0
Gender of the patients 4.996 1 0.025
The highest level of education attained 22.451 8 0.004
Cross tabulations between Hypertension and other variables
Symptomatic patients 3.045 1 0.081
Age of the patients 35.169 4 0
Gender of patients 1.187 1 0.276
The highest level of education attained 21.624 8 0.006
Cross tabulations between obesity and other variables
Symptomatic patients 0.173 1 0.678
Age of patients 1.272 4 0.866
Gender of patients 1.512 1 0.219
The highest level of education attained 2.083 8 0.978
Cross tabulations between Asthma and other variables
Symptomatic patients 0.092 1 0.762
Age of patients 3.77 4 0.438
Gender of patients 2.811 1 0.094
The highest level of education attained 10.379 8 0.239
Cross tabulations between Cancer and other variables
Symptomatic patients 1.22 1 0.269
Age of patients 1.747 4 0.782
Gender of patients 3.144 1 0.076
The highest level of education attained 12.648 8 0.125
Cross tabulations between HIV and AIDS and other variables
Symptomatic patients 0.07 1 0.791
Age of patients 8.515 4 0.074
Gender of patients 3.646 1 0.056
The highest level of education attained 2.107 8 0.978

Table 5: Cross tabulations between variables in COVID-19 patients treated at Gulu Regional Referral Hospital.

Variables   Frequency Percent (%)
Duration of Hospital Stay (Weeks) less than a week 56 11.6
One 216 44.9
Two 158 32.8
Three 39 8.1
Four 5 1
Five 4 0.8
Six 3 0.6
Oxygen saturation at admission (SpO2) <80 7 1.5
80-96 80 16.6
>96 394 81.9
Aspirin Yes 2 0.4
No 479 99.6
Antibiotics Yes 480 99.8
No 1 0.2
Vitamin D Yes 23 4.8
No 458 95.2
Steaming Yes 2 0.4
No 479 99.6
Vitamin C Yes 385 80
No 96 20
Ivermectin Yes 7 1.5
No 474 98.5
Lemon Yes 3 0.6
No 478 99.4
Ginger Yes 1 0.2
No 480 99.8
Garlic Yes 2 0.4
No 479 99.6
Steroids Yes 66 13.7
No 415 86.3

Table 6: Characteristics of COVID-19 patients treated at Gulu Regional Referral Hospital.

In Table 7, factors associated with COVID-19 patients treated at Gulu Regional Referral Hospital were Diabetes mellitus χ2=1.156; df=1; p<0.0000; other cardiovascular diseases (CVDs) χ2=34.819; df=1; p<0.0000; hypertension χ2=10.807; df=1; p=0.0010; HIV and AIDs χ2=6.488; df=1; p=0.011; treatment with steroids χ2=157.639; df=1; p<0.0000;Vitamin D χ2=113.521; df=1; p<0.0000; vitamin C χ2=56.548; df=1; p<0.0000; Ivermectin χ2=82.886; df=1; 0.0000; Oxygen saturation(SpO2) 80-96 χ2=29.357; df=1; p<0.0000; Oxygen saturation (<96) χ2=42.962; df=1; p<0.0000; duration of hospital stay (less than one week) χ2=57.690; df=1; p<0.0000; duration of hospital stay (two weeks) χ2=6.569; df=1; p=0.010 and duration of hospital stay (six weeks) χ2=4.180; df=1; 0.041.

 Variables Freq (n=664) χ2 df p-value
Duration of symptoms (1-7 days) 236(35.5%) 1.101 4 0.894
Diabetes Mellitus 38(5.7%) 51.156 1 0
Chronic obstructive pulmonary diseases (COPDs) 8(1.2%) 1.041 1 0.307
Other Cardiovascular diseases (CVDs) 58(8.7%) 34.819 1 0
Hypertension 83(12.5%) 10.807 1 0.001
Obesity 3(0.5%) 0.153 1 0.696
Asthma 15(2.3%) 0.113 1 0.737
Cancers 4(0.6%) 3.565 1 0.059
HIV and AIDS 61(9.2%) 6.488 1 0.011
Pregnancy 1(0.2%) 1.011 1 0.856
Other comorbidities 40(6.0%) 37.013 1 0
Symptomatic 509(76.7%) 2.17 1 0.141
Age (>50 years) 129(19.4%) 40.601 1 0
Gender (Females) 221(33.3%) 7.986 1 0.0005
The highest level of education attained (graduates) 72(10.8%) 39.213 1 0
Steroids (1) 66(13.7%) 157.639 1 0
Aspirin (1) 2(4.16%) 0.124 1 0.725
Antibiotics (1) 480(99.8%) 0.062 1 0.804
Vitamin D (1) 23(4.8%) 113.521 1 0
Steaming (1) 2(0.4%) 0.124 1 0.725
Vitamin C (1) 385(80.0%) 56.548 1 0
Ivermectin (1) 7(1.5%) 82.886 1 0
Garlic (1) 2(0.4%) 0.124 1 0.725
Ginger (1) 1(0.2%) 0.062 1 0.804
Lemon (1) 3(0.6%) 0.186 1 0.666
Oxygen Saturation (SpO2) (<80) 7(1.5%) 49.799 2 0
Oxygen Saturation (SpO2) (80-96) 80(16.6%) 29.357 1 0
Oxygen Saturation (SpO2) (>96) 394(81.9%) 42.962 1 0
Duration of Stay (Less than one week) 56(11.6%) 57.69 6 0
Duration of Stay (One week) 216(44.9%) 1.93 1 0.165
Duration of Stay (Two weeks) 158(32.8%) 6.569 1 0.01
Duration of Stay (Three weeks) 39(8.1%) 2.69 1 0.101
Duration of Stay (Four weeks) 5(1.0%) 0.312 1 0.577
Duration of Stay (Five weeks) 4(0.8%) 0.249 1 0.618
Duration of Stay (Six weeks) 3(0.6%) 4.18 1 0.041
Overall Statistics   256.221 18 0

Table 7: Factors associated with COVID-19 patients treated at Gulu Regional Referral Hospital CTU.

In Table 8, the Adjusted Odds Ratios (AOR) for factors associated with COVID-19 patients treated at Gulu Regional Referral Hospital. Treatment with steroids AOR=138.835 at 95% CI: 12.258-1572.50; p<0.000 and Vitamin D AOR=0.016 at 95% CI:1.902-520.98; p=0.016.

    B S.E. Wald df Sig. Exp (B) 95% C.I. for Exp (B)
Lower Upper
Step 1a Steroids (1) 4.933 1.238 15.87 1 0 138.835 12.258 1572.5
Aspirin (1) -18.74 26237.08 0 1 0.999 0 0 0
Antibiotics (1) 14.645 40192.96 0 1 1 2292669 0 0
Vitamin D (1) 3.449 1.432 5.803 1 0.016 31.478 1.902 520.975
Steaming (1) -20.277 40192.97 0 1 1 0 0 0
Vitamin C (1) -0.42 0.68 0.38 1 0.537 0.657 0.173 2.494
Ivermectin (1) 3.504 3.438 1.039 1 0.308 33.262 0.039 28095.88
Garlic (1) 4.933 56841.43 0 1 1 138.833 0 0
Ginger (1) 16.441 69616.26 0 1 1 13810167 0 0
Lemon (1) -19.579 40192.87 0 1 1 0 0 0
Oxygen (SpO2) <80)     1.124 2 0.57      
Oxygen (80-96) 0.174 1.502 0.013 1 0.908 1.19 0.063 22.603
Oxygen (>96) 0.873 1.5 0.338 1 0.561 2.393 0.126 45.291
DoS (<1week)     7.14 6 0.308      
DoS (1 week) 1.126 0.723 2.423 1 0.12 3.082 0.747 12.718
DoS (2 weeks) 2.222 1.188 3.498 1 0.061 9.229 0.899 94.744
DoS (3 weeks) 18.867 5359.821 0 1 0.997 1.56E+08 0 0
DoS (4 weeks) 19.883 15112.35 0 1 0.999 4.32E+08 0 0
DoS (5 weeks) 15.986 19996.24 0 1 0.999 8765685 0 0
DoS (6 weeks) -2.766 2.391 1.338 1 0.247 0.063 0.001 6.825
Constant 29.894 47998.53 0 1 1 9.61E+12    

Table 8: Multivariable logistic regression showing treatment, Oxygen saturation (SpO2), and duration of hospital stay for COVID-19 patients treated at GRRH.

Discussion

The most significant findings were the three waves of COVID-19 in Gulu in Northern Uganda, and these were in May and September of 2020 and July of 2021 (Figures 1-3). The third wave of COVID-19 in 2021 was less pronounced (Figures 1-3). This finding contrasts with the official Ugandan Ministry of Health position on the number of COVID-19 waves Uganda has gone through since the pandemic began in March 2020. The Ugandan Ministry of Health specified two waves of the COVID-19: one in 2020 and another in June 2021. This Ugandan Ministry of Health report is not surprising as regional waves of COVID-19 have been reported in many studies [11-14]. This finding has implications on how Uganda could respond to the COVID-19 waves as the regional approach to managing and controlling the pandemic has become eminent. The regional occurrence of the COVID-19 wave has advantages in that the Ugandan Ministry of Health could use this information to harness support and allocate resources to effectively manage and control the pandemic at the regional level in different parts of the Country. This may include mass mobilization and sensitization of the population at a regional level to embrace mass vaccination with the COVID-19 vaccines now that they are available in the Country. It is expected that this approach could limit the spreading of COVID-19 country-wide and reduce the morbidity and mortality of the coronavirus in Northern Uganda.

Infectious-Diseases-admissions

Figure 1: The pattern of COVID-19 admissions to the Gulu Treatment Unit (CTU).

Infectious-Diseases-patients

Figure 2: The pattern of discharges of COVID-19 patients treated at the CTU of Gulu Regional Referral Hospital.

Infectious-Diseases-hospital

Figure 3: Duration of hospital stays (days) of COVID-19 patients treated at Gulu Regional Hospital.

Socio-demographic characteristics of the COVID-19 patients

Findings from this study show that most COVID-19 patients treated at the Gulu Regional Referral Hospital were males, 30-39 years-old, Acholi, Catholics with certificates as the highest level of education, civil servants, and from Gulu District (Table 1). These socio-demographic characteristics are comparable to previous studies conducted in Northern Uganda, where the most affected people were males and certificates at their highest level of education attained (Table 1). What is different in this study population is that the most affected age group is a decade older (Table 1) compared to previous studies in Northern Uganda, where most participants were 20–29-years-old [15,16].

The age factor could be explained by the susceptibility pattern of the COVID-19 among the older population of Northern Uganda and elsewhere. The aging population appears more vulnerable and susceptible. The overall reasons for the susceptibility in the older people in Northern Uganda may not be known for now but perhaps attributable to lifestyles, exposure to multiple risk factors, comorbidities, and immunity problems of the more aging population. As shown in Table 1, the younger age groups were least affected as per the GRRH COVID-19 treatment centre's admission details. However, it could also mean that many of the younger age groups got affected but remained asymptomatic, did not test for COVID-19, did not develop severe disease, and did not get hospitalized with the coronavirus.

Findings from this current study show that nearly one-fourth of the COVID-19 patients treated were asymptomatic, and less than 10% of the patients were below 20 years of age (Table 3). These authors argue that this information was not wholly new. Similar findings in many studies conducted elsewhere in the world show that younger persons were least susceptible to severe COVID-19 and chances of hospitalization [13,14,17].

Factors associated with the COVID-19 patients treated at the Gulu Regional Referral Hospital

This report shows that most COVID-19 patients treated for severe COVID-19 and died at the GRRH had comorbidities, for example, Diabetes mellitus, cardiovascular diseases (CVDs) including (Stroke, valvular heart diseases, dysrhythmias, heart failure, and cardiac septal defects), hypertension, and symptomatic cases (Tables 2 and 3). Many studies have observed similar findings, particularly those with comorbidities [2,17,18]. This finding implies that the Ugandan Ministry of Health could adopt the "Enhanced shielding" approach, where persons with comorbidities and the elderly are shielded from the general population to protect them from contracting the COVID-19 virus [12,19]. These suggestions have implications on the approach the Ugandan health systems could adopt to control the spreading of COVID-19 among the elderly and those with comorbid conditions. The rural structure and relationship between the elderly and younger generation need thorough analysis as the elderly in the rural communities live with and together with young people who provide support and protection to the elderly. The practicality of this approach needs thorough thinking as this new approach may disrupt traditional ways of how people in the African rural communities live. These authors argue that with the lockdown, the economy, and health systems collapsing in many African countries, it is high time government planners came with solutions that allow the economy to be opened but ensure a reduced incidence and prevalence of COVID-19 in communities. One of the recommended approaches was to practice the enhanced shielding approach, which is more favourable to a country's social and economic systems. In addition, there is a need to sensitize and mobilize the population to embrace mass COVID-19 vaccination as vaccines are now available in the country to reduce the incidence of severe COVID-19, which require hospitalization.

Treatment and complications observed among COVID-19 patients in Gulu Regional Referral Hospital

Findings from this study show that most COVID-19 patients were treated with antibiotics, vitamin C, steroids, Ivermectin, and vitamin D (Tables 3-7) and the outcomes of the treatment have been encouraging as shown by the very high recovery rate at 95.2% and a statistically significant association with steroid and Vitamin D treatment (Table 8).

In the same study, the most typical complications observed among the COVID-19 patients were pneumonia, acute respiratory distress syndrome (ARDS), systemic infections, septic shock, chronic fatigue, depression, and nightmares (Table 4). These authors argue that there were justified reasons for using antibiotics in treating COVID-19 patients at Gulu Hospital, as many cases developed complications treated with antibiotics.

In addition, the role played by the other drugs in the management of COVID-19 was suggested by scholars and academicians across the world and particularly their use as immune system modulators [17]. To come up with a conclusive decision on the beneficial effects of the two drugs for managing COVID-19 patients at GRRH, formal Randomized Controlled Trials will be required.

On the mental health complications observed among the COVID-19 patients treated at the Gulu Regional Referral Hospital, authors recommend comprehensive mental health support for COVID-19 patients and the follow-up after recovery. Effective management of mental health conditions such as depression relieves the ever-increasing sense of depression and isolation experienced by the COVID-19 patients. If the numbers of mental health cases become widespread, a grass-root approach using trained village health teams (VHTs) would be the recommended approach for handling the problem. Notably, the VHTs should be trained and capable of dealing with COVID-19 related Psychosocial symptoms in the community. This idea is supported by studies conducted elsewhere in Africa, which suggest a grass-root approach to mental health problems after African countries’ lockdown [12,19].

The independent determinants of COVID-19 cases treated at Gulu Regional Referral Hospital

This study showed that the recovery rate from the COVID-19 treated at the Gulu Hospital was 95.2%, yet 99.5% of the COVID-19 patients were unvaccinated (Table 3). Furthermore, this study found the Adjusted Odds Ratios (AOR) for factors associated with COVID-19 patients’ recovery at GRRH were treatment with steroids AOR=138.835 at 95% CI:12.258-1572.50;p<0.000 and Vitamin D AOR=0.016 at 95% CI:1.902-520.98;p=0.016 (Table 8). Statistically significant associations of Vitamin D and steroids with favourable treatment and management outcomes of COVID 19 patients in our study have also been observed in previous studies [20,21]. Could these successes be specific for this centre, or could this apply to diverse settings worldwide? A formal review study in different locations would be required in the long term to determine the effectiveness of the drugs in managing mild and severe cases of COVID-19. Authors recommend global studies on the two drugs to assess their effects on the treatment outcomes of COVID-19 patients.

Circumstances under which the coronavirus infected participants

Findings show that most of the circumstances were unknown 581(87.5%), others were congregated situations such overcrowding at Elegu border and interacting with international truck drivers 50(7.5%), Aswa dam construction workers 12(1.8%) who lived in dormitories, health facility 2(0.3%), persons who nursed a relative with COVID-19 2(0.3%), bars 1(0.2%) and others 16(2.4%). This finding implies that the known source of the COVID-19 infection in Northern Uganda was from contacts with international truck drivers and mainly at the Elegu border point. Other sources such as bars, churches, and markets were fewer. Authors argue that regional controls of COVID-19 would be ideal for the East African region, where there is brisk trade among the countries. Therefore, the management and surveillance of international truck drivers as a regional approach would be suitable for controlling the coronavirus, ensuring that COVID-19 testing and management are conducted as per the international protocols across all the East African countries [11].

Strengths and Limitations of the Study

This study was a retrospective review of datasets from the COVID-19 medical records of Gulu Regional Referral Hospital. The period of the evaluation was from March 2020 to October 2021. The study has limitations on how Gulu Hospital handled records and record keeping. In addition, vital information, for example, weight, height, and BMI of COVID-19 patients, was not recorded due to the emergency handling of the cases at the beginning of the pandemic in March 2020. The missing variables in the Gulu Hospital HMIS records excluded some files from participating in this study. In this, authors have suggested a need for a prospective or longitudinal assessment of the COVID-19 cases in the future, ensuring that all data were measured and recorded accordingly.

This data is vital as it is one of the well-documented completed data for over 664 cases of COVID-19 treated in a Regional Referral Hospital in Uganda. Findings from this study show tremendous and good clinical practices at Gulu Regional Referral Hospital despite the challenges faced during the pandemic.

Generalization of the Data from this Study

These findings should be cautiously interpreted and generalized only to Regional Referral Hospitals in Uganda. However, they could be similarly observed in many hospitals in African countries with lowresource settings.

Conclusion

This study shows successful management of COVID-19 patients in low resource settings in Gulu Regional Referral Hospital with a recovery rate of 95.2%. The pattern of admission to the Hospital suggests Uganda has experienced three waves of COVID-19, contrary to the official government position of two waves. Treatment of COVID-19 patients with steroids and Vitamin D is associated with recovery of COVID 19 patients. However, there is a need for Randomized Controlled Trials to determine the actual effects of these drugs in the treatment of COVID-19 infections.

Declarations

Ethics approval and consent to participate

The Gulu Regional Referral Hospital Institutional and Ethics Committee approved this study. In addition, the study was conducted following the relevant institutional guidelines and regulations.

Availability of Data and Material

All datasets supporting the conclusion in this article is within this article and is accessible by a reasonable request to the corresponding author.

Competing Interests

All authors declare no conflict of interest.

Funding

Most funding for this study was contributions of individual research members of the Uganda Medical Association (UMA) Acholi branch.

Authors Contributions

DLK, ENI, PL, JNO, JA, and FWDO participated in designing the study, SB and DLK were responsible for data abstraction supervision, BS, JA, ENI, and DLK were responsible for data analysis, interpretation, writing, and CO, NAO, WAO, BT, JE, PA, PL, FPP, DA, JNO, FWDO, for revising the manuscript.

Acknowledgment

We acknowledge with many thanks to the support from the administration of Gulu Regional Referral Hospital for the information obtained. Dr. Laban Oketcho, Dr. Anek Janet Schola, Dr. Baguma Steven, and Mr. Dominic Ogwal Savio for the well-collected data from the archives of Gulu Regional Referral Hospital. We also thank Mr. Lawrence Obalim for the data analysis well conducted. In addition, financial support from UMA Acholi branch members, which enabled the team to conduct this study successfully, is most appreciated. In honour of our two fallen colleagues (Co-authors), Dr. Paska Layet and Dr. Oola Janet, may their souls rest in peace!

References

  1. Wu Z, McGoogan JMJJ (2020) Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72314 cases from the Chinese center for disease control and prevention. JAMA 323: 1239-1242.
  2. Bialek S, Boundy E, Bowen V, Chow N, Cohn A, et al. (2020) Severe outcomes among patients with coronavirus disease 2019 (COVID-19)-United States. February 12-March 16, 2020. CDC 69: 343-346.
  3. Wang D (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 23: 1061-1069.
  4. Mez J, Daneshvar DH, Kiernan PT (2017) Clinicopathological evaluation of chronic traumatic encephalopathy in American football players. JAMA 318: 360-370.
  5. Udugama B, Kadhiresan P, Kozlowski HN (2020) Diagnosing COVID-19: The disease and tools for detection. ACS Nano14: 3822-3835.
  6. Li T, Lu H, Zhang W (2020) Clinical observation and management of COVID-19 patients. Emerg Microbes Infect 9: 687-690.
  7. Gao J, Tian Z, Yang XJBT (2020) Breakthrough Chloroquine phosphate has shown apparent efficacy in the treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 14: 72-73.
  8. Elfiky AA (2020) Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci 248: 117477.
  9. Chen C, Huang J, Cheng Z (2020) Favipiravir versus arbidol for COVID-19: A randomized clinical trial. MedRxiv 12: 683296.
  10. Fadel R, Morrison A, Vahia A (2020) Short-course corticosteroids in hospitalized patients with COVID-19. Clin Infect Dis 71: 2114-2120.
  11. Kitara DL, Ikoona EN (2020) COVID-19 pandemic, Uganda's Story. Pan Afr Med J 35: 51.
  12. Kitara DL, Ikoona EN (2021) Proposed strategies for easing COVID-19 lockdown measures in Africa. Pan Afr Med J 36: 10.
  13. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72314 cases from the Chinese center for disease control and prevention.
  14. Petrov AN, Welford M, Nikolay J, DeGroote GJ, Devlin M, et al. (2021) The second wave of the COVID-19 pandemic in the Arctic: regional and temporal dynamics. Int J Circumpolar Health 80: 1925446.
  15. Kitara DL, Karlsson O (2020) The effects of economic stress and urbanization on driving behaviours of Boda-boda drivers and accidents in Gulu, Northern Uganda: A qualitative view of drivers. Pan Afr Med J 36: 47.
  16. Ayugi J, Ndagijimana G, Luyima S, Kitara DL (2021) Breast cancer awareness and downstaging practices among adult women in the Gulu City Main Market, Northern Uganda: A cross-sectional study. Research Square.
  17. Kirenga B, Muttamba W, Kayongo A (2020) Characteristics and outcomes of admitted patients infected with SARS-CoV-2 in Uganda. BMJ Open Resp Res 7: 000646.
  18. Guan WJ, Ni ZY, Hu Y (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382: 1708-1720.
  19. Kitara DL, Ikoona EN (2020) A proposed framework to limit post-lockdown community transmission of COVID-19 in Africa. Pan Afr Med J 38: 303.
  20. Garg S, Kim L, Whitaker M (2020) Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019-COVID-NET, 14 States, March 1-30, 2020. MMWR Morb Mortal Wkly Rep 69: 458-464.
  21. Naushad Ali (2020) Role of vitamin D in preventing COVID-19 infection, progression, and severity. J Infect Public Health 13: 1373-1380.

Citation: Okot C, Baguma S, Onira NA, Agings WO, Arwinyo D, et al. (2022) Characteristics of the COVID-19 Patients Treated at Gulu Regional Referral Hospital, Northern Uganda: A Cross-Sectional Study. J Infect Dis Ther S6:003.

Copyright: © 2022 Okot C, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Top